Glenmark and Ichnos take a collaborative leap to accelerate innovation in finding cure for cancer with their alliance - ‘Ichnos Glenmark Innovation’. This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors.

Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors  and Hodgkin’s Lymphoma

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older

Glenmark’s leading respiratory pipeline candidate Ryaltris™, formerly GSP 301 Nasal Spray, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, accepted by the US FDA for review as a treatment for seasonal allergic rhinitis.

Ryaltris (formerly GSP 301 Nasal Spray), a combination steroid plus antihistamine nasal spray for the treatment of allergic rhinitis, has completed three Phase 3 trials and is preparing for an NDA submission in CY 18.

Glenmark launched ezetimibe, the first and only generic version of Zetia® in the United States for the treatment of high cholesterol.

With the addition of GBR 1372, a bispecific monoclonal antibody from Glenmarks’s BEAT® technology platform, Glenmark has three clinical candidates targeting oncology indications.

Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.

Glenmark commissioned a new manufacturing facility in North Carolina, US for development of injectable and oral solid dosages.

In the same year, Glenmark also set up a new antibody manufacturing facility in La Chaux-de-Fonds, Switzerland for development of clinical GMP-grade biologics for clinical trials.

Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor. Glenmark received USD 15 Mn payment from Forest Labs on an option agreement

Glenmark out-licensed its first novel biological entity GBR 500 to Sanofi-Aventis and received an upfront payment of USD 50 Mn and a milestone payment of USD 5 Mn in May 2014

Glenmark entered into an out-licensing deal with Sanofi-Aventis for its molecule GRC 15300, a first-in-class TRPV3 antagonist. Glenmark received an upfront payment of USD 25 million

Eli Lilly acquired the rights to a portfolio of TRPV1 antagonist molecules developed by Glenmark. Glenmark received an upfront fee of USD 45 Mn

To focus on development of novel biologics, Glenmark established its first R&D center for NBE research in Switzerland.

Out-licensing deal for novel molecule Melogliptin
Glenmark entered into an out-licensing deal with Merck KGaA for its molecule Melogliptin and received a total payment of USD 31 million.

Glenmark launched front-end commercial sales in the US in 2005. To support its US operations with high quality products, it set up a manufacturing facility built to US FDA specifications at Goa, India.

Glenmark entered into a deal with Teijin Pharma for the Japan rights of its molecule Oglemilast for which it received an upfront payment of USD 6 Mn

Glenmark created history where it sealed its first out-licensing deal with Forest Laboratories for GRC 3886. Glenmark received USD 35Mn as upfront and milestone payments

Glenmark forayed into manufacturing of APIs and commenced operations at the Kurkumbh API manufacturing facility in Maharashtra. In the following year expanding further, Glenmark also acquired API manufacturing facility at Ankleshwar, Gujarat.

Glenmark was first listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India at a market capitalization of $40 million.

Glenmark entered the dermatology market with the launch of ‘Candid cream’.

Dermatology is a key focus area for Glenmark even today, for both formulations and novel drug discovery worldwide.

Glenmark was established in 1977 by our Founder Emeritus Late Mr. Gracias Saldanha.